Travere Therapeutics (TVTX) Expected to Release Earnings on Tuesday

Travere Therapeutics (NASDAQ:TVTX) will likely be releasing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Travere Therapeutics to announce earnings of ($0.1346) per share and revenue of $157.2660 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. The company had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.47) EPS. On average, analysts expect Travere Therapeutics to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $55.89 on Monday. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 3.16. The company has a fifty day simple moving average of $53.56 and a 200-day simple moving average of $40.28. The stock has a market cap of $5.20 billion, a P/E ratio of -242.99 and a beta of 1.10. Travere Therapeutics has a 12-month low of $15.03 and a 12-month high of $60.10.

Insiders Place Their Bets

In other Travere Therapeutics news, Director Timothy Coughlin sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $50.07, for a total value of $500,700.00. Following the completion of the sale, the director owned 56,250 shares in the company, valued at approximately $2,816,437.50. The trade was a 15.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 4,500 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $50.00, for a total value of $225,000.00. Following the completion of the sale, the director directly owned 41,500 shares of the company’s stock, valued at $2,075,000. The trade was a 9.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 55,663 shares of company stock worth $2,570,462. Corporate insiders own 4.44% of the company’s stock.

Institutional Trading of Travere Therapeutics

Large investors have recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its stake in Travere Therapeutics by 69.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after purchasing an additional 487 shares during the period. State of Wyoming purchased a new position in shares of Travere Therapeutics during the fourth quarter worth about $37,000. Captrust Financial Advisors increased its position in Travere Therapeutics by 9.3% in the 4th quarter. Captrust Financial Advisors now owns 20,703 shares of the company’s stock valued at $791,000 after acquiring an additional 1,767 shares during the period. Raymond James Financial Inc. purchased a new stake in Travere Therapeutics during the 2nd quarter valued at approximately $33,000. Finally, Swiss National Bank lifted its position in Travere Therapeutics by 1.6% during the 3rd quarter. Swiss National Bank now owns 163,600 shares of the company’s stock worth $3,910,000 after acquiring an additional 2,500 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on TVTX shares. Wells Fargo & Company lifted their price target on Travere Therapeutics from $50.00 to $65.00 and gave the stock an “overweight” rating in a report on Friday, June 12th. Weiss Ratings cut Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Citigroup increased their price target on shares of Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 15th. Wedbush raised their price objective on shares of Travere Therapeutics from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Monday, June 22nd. Finally, Guggenheim boosted their price objective on shares of Travere Therapeutics from $56.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.58.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.